MANKIND - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 3.5

📉 Optimal Entry Price: ₹2,300–₹2,350 (near support and RSI zone)

📈 Exit Strategy (if holding): ₹2,700–₹2,750 (approaching resistance and DMA levels)

🔷 Positive

• 📊 EPS of ₹45.1: Indicates solid earnings performance.
• 📈 ROCE (15%) and ROE (13.9%): Reflect decent capital efficiency.
• 📈 Volume above 1-week average: Suggests rising interest despite price dip.
• 📈 Trading near DMA 50 and 200: Offers potential bounce if support holds.
• 📈 DII holding increased by 0.41%: Indicates domestic institutional confidence.

⚠️ Limitation

• 📉 High P/E of 54.0: Significantly above industry average (33.1), indicating overvaluation.
• 📉 PEG ratio of 6.42: Suggests poor valuation relative to growth.
• 📉 RSI at 35.3: Near oversold zone, but not yet signaling reversal.
• 📉 MACD at -28.8: Indicates bearish momentum.
• 📉 Dividend yield of 0.04%: Minimal income return for investors.

📉 Company Negative News

• 📉 Q2FY26 profit fell 13.4% QoQ, raising concerns over margin pressure and valuation sustainability.
• 📉 FII holding declined by 0.24%, reflecting cautious foreign sentiment.

📈 Company Positive News

• 📊 Mankind Pharma reported 8% YoY revenue growth in Q2FY26, driven by domestic formulations.
• 📈 Management remains optimistic about rural demand and chronic care segment expansion.

🏥 Industry

• 💊 Operates in the pharma sector, which remains resilient with growing demand for chronic and lifestyle treatments.
• 📈 Industry P/E of 33.1 suggests Mankind is trading at a premium, possibly due to brand strength and growth expectations.

🧾 Conclusion

• ⚠️ Mankind Pharma is a cautious swing trade candidate with strong fundamentals but technical weakness and valuation concerns.
• 📌 Entry near ₹2,300–₹2,350 offers a low-risk setup if RSI rebounds and MACD stabilizes.
• 🚪 If already holding, consider exiting near ₹2,700–₹2,750, aligning with resistance and DMA levels.

I can also compare Mankind Pharma with another pharma stock like Cipla or Sun Pharma to refine your swing strategy.